Search
  • Biocelect

Rapivab

Biocelect is excited to announce its partnership with BioCryst Pharmaceuticals Inc. As a result Biocelect is now the exclusive distributor in Australia for Rapivab (peramivir) a neuraminidase inhibitor for the treatment of acute influenza. An exciting addition to our expanding product range.

Rapivab is the only TGA approved intravenous influenza antiviral available on the current market.


Please view the Rapivab Product page below.





Biocelect Logo_Colour.png

Copyright 2019 Biocelect 

Australian Office: Suite 502, 139 Macquarie Street, Sydney NSW 2000, Australia

Registered Office Australia: Suite 405, Level 4, 51 Rawson Street, Epping NSW, 2121,  Australia 

Registered Office New Zealand: Level 5, Wynn Williams House, 47 Hereford Street, Christchurch 8013, New Zealand

Biocelect acknowledges the Traditional Custodians of Australia and their continued connection to land,

sea and community. We pay our respects to the Elders, past and present. 

Privacy Policy

  • LinkedIn Social Icon